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Abstract. Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted 
therapy trials have thus far been disappointing due to a lack of robust 
stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases 
demonstrates that this is a heterogeneous cancer dominated by copy number 
alterations with frequent large scale rearrangements. Co-amplification of 
receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is 
almost ubiquitous; thus tailored combination RTKi therapy might be required, as 
we demonstrate in vitro. However, mutational signatures reveal three distinct 
molecular subtypes with potential therapeutic relevance, which we verify in an 
independent cohort (n=87): i) enriched for BRCA signature with prevalent defects 
in the homologous recombination pathway; ii) dominant T>G mutational pattern 
associated with a high mutational load and neoantigen burden; iii) C>A/T 
mutational pattern with evidence of an aging imprint. These subtypes could be 
ascertained using a clinically applicable sequencing strategy (low coverage) as a 
basis for therapy selection. 
 
Esophageal cancer is the eighth most common cancer world-wide, and the sixth most 
common cause of cancer-related deaths [1]. There are two main subtypes, squamous 
and adenocarcinoma, and the incidence of EAC has increased 4.6-fold amongst white 
males in the US over the past three decades [2]. It is an aggressive disease, with early 
loco-regional spread, resulting in a median overall survival of less than a year [3].  
Curative treatment has been based on esophagectomy, with the addition of peri-
operative chemotherapy or chemoradiotherapy improving survival [4-6]. The use of  
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molecularly targeted agents has lagged behind that of other cancers and the results so 
far have been disappointing. Indeed, only Trastuzumab treatment has led to any 
improvement in outcomes, and this was only in HER2 positive cases, in metastatic 
disease [7]. Advances in this area have been hampered by the lack of understanding of 
the molecular drivers of this cancer. 
Major sequencing efforts have enabled new classifications of cancers based on their 
molecular parameters [8, 9]. The emerging genomic biomarkers are based on single 
nucleotide mutations, structural rearrangements and mutational signatures [10-14], and 
in some instances these have started to lead to the development of stratified trials with 
the promise of improved outcomes for patients [15]. 
Exome sequencing and a small number of whole-genome sequences have uncovered a 
limited number of potential driver mutations in EAC. However, as many of the mutations 
occur in tumor suppressor genes (TP53, SMAD4, ARID1A), actionable oncogenic 
mutations have remained elusive [16, 17]. What is emerging is a picture of genomic 
instability with complex rearrangements leading to significant heterogeneity between 
patients [18]. What is still lacking is an understanding of how to use these complex 
molecular data to stratify patients to help inform clinical decision making.  
Here, we present WGS data for over 100 cases performed as part of the International 
Cancer Genome Consortium, with verification of key findings in independent cohorts. 
We have used genomic information coupled with expression data and in vitro 
experiments to better understand the failure of targeted therapies and to uncover 
mechanisms of disease pathogenesis that may inform tumor classification and therapy 
selection. 
 
 
RESULTS 
 
Large-scale alterations dominate the EAC landscape 
 
WGS data from 129 EAC patients (including tumors from the gastroesophageal junction, 
Siewert type 1 and 2) have allowed us to comprehensively catalog the genomic 
alterations in this cancer, including the large-scale structural rearrangements not 
detectable from exome sequencing. The clinical characteristics of the cohort are typical 
for the disease (Supplementary Table 1). 
As previously noted, point mutations are abundant in this cancer [16]. However, the 
overall genomic landscape suggests a disease driven by structural variation and copy 
number changes (Fig. 1 and Supplementary Fig. 1). Analysis of a combined cohort of 111 
EAC cases from TCGA [19] and Nones et al [20] confirms a dominance of copy number 
alterations, compared to point mutations, in the majority of cases (Supplementary Fig. 
2). 
When examining the specific loci affected, potential gene driver events were highly 
heterogeneous between cases, and structural changes again dominated (Fig. 1). For 
example, when considering genes altered in 10% or more of cases, many more were 
rearranged, amplified or deleted than were affected by indels or nonsynonymous point 
mutations. We observed novel recurrently rearranged genes, including SMYD3 in 39% 
of cases, RUNX1 27%, CTNNA3 22%, RBFOX1 21%, the CDKN2A/2B locus 18%, CDK14 
16%, JUP 12% (important transcriptional, signalling and cell communication regulators), 
and fragile sites (FHIT 95%, WWOX 84%, MACROD2 64%). Somatic L1 mobile element 
insertions were also abundant. Detecting inserts that had transduced unique flanking 
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sequences identified an average of 25 inserts/tumor (range 0 to 1127), including those 
already known to transduce [21, 22] and novel examples. These numbers are 
substantially higher than previously reported [21] because of improved sensitivity. 
Mobile element insertions were found in signalling, cell cycle and cell adhesion 
regulators: ERBB4 - 6/129, CTNNA3 – 5/129, CTNNA2 – 4/129, CDH18 – 3/129, SOX5 – 
2/129, CDK12 – 1/129. 
Significantly amplified loci according to GISTIC2.0 [23] (7q22, 13q14, 18q11, 11q13 
etc.) comprised genes like ERBB2, EFGR, RB1, GATA4/6, CCND1, MDM2 among others, 
while the top significantly deleted loci in the cohort (9p21, 21p11, 3p14, etc.) showed 
losses of e.g. CLDN22, CDKN2A, CKN2B, as well as several fragile sites (Supplementary 
Fig. 3 and Supplementary Tables 2 and 3).  
The most frequent somatic mutation/indel events included a number of known driver 
genes with roles in DNA damage, signal transduction, cell cycle and chromatin 
remodelling. Seven of these reached statistical significance as likely driver genes, as 
inferred by MutSigCV [24] (Fig. 1e and Supplementary Table 4): TP53 (81%), ARID1A 
(17%), SMAD4 (16%), CDKN2A (15%), KCNQ3 (12%), CCDC102B (9%), CYP7B1 (7%), 
largely as previously described [16, 17]. In addition SYNE1 was mutated in 23% of cases, 
but did not reach significance by MutSigCV. 
The  high frequency of genomic catastrophes observed in our cohort was consistent 
with a significant role of larger-scale events in this disease - chromothripsis: 39/129 
patients (30%), kataegis: 40/129 (31%), complex rearrangement events: 41/129 (32%), 
(Methods, Fig. 1f and Supplementary Fig. 4-7). The complex rearrangements included: 
focal amplifications with BFB pattern (11/129, 9%); focal amplifications <5Mb-wide 
with irregular copy number amplification steps (26/129, 20%); focal amplifications 5-
10 Mb-wide with symmetric copy number amplification steps (10/129, 8%); double 
minute-like patterns (3/129, 2%); and subtelomeric BFBs (1/129, 1%) (Supplementary 
Fig. 7). The chromothripsis and BFB/complex rearrangement event frequencies were in 
a similar range to that described by Nones et al [18] – 33% and 27%, respectively. 
Kataegis rates were lower than that previously reported (19/22 = 86%), likely due to 
our more stringent criteria for calling (Methods). An enrichment of C>T and C>G 
mutations was observed in kataegis regions, as previously reported [25] 
(Supplementary Fig. 5).  
Hence, this is a heterogeneous cancer dominated by copy number alterations and 
large scale rearrangements. Clinically meaningful genomic subgroups relevant for 
therapy are not immediately apparent from these analyses. 
 
 
Receptors and downstream RTK targets are pervasively disrupted in EAC  
 
Next we examined the genomic data to understand possible reasons for the 
disappointing results seen with many of the trials targeting growth factor receptors. 
Resistance to RTK therapy generally results from co-amplifications of alternative RTKs 
or amplification/activation of downstream mitogenic pathways. In our cohort we 
observed widespread gene amplification across multiple RTKs, as well as within the 
MAPK and PI3K pathways. Such patterns were similar among endoreduplicated and 
non-endoreduplicated samples, as well as in a panel of cell models (Fig. 2a, 2b).  
When considering high level amplifications (GISTIC cut-off greater than 2), we report 
similar rates to those reported previously for EGFR and HER2 [26, 27]. HER2 was the 
most amplified RTK (22/129 patients = 17%), followed by EGFR (14/129 patients = 
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11%). Other commonly over-expressed RTKs included MET and FGFR.  All these 
receptors are targeted in clinical trials with ongoing recruitment [28]. When considering 
lower level amplifications across these RTKs and downstream signaling pathways 
(GISTIC >1), these are highly prevalent and may still have biological significance 
accounting for disappointing trial results. 
We used microarray expression data for available cases to check the consequences of 
the observed gains/losses at the transcriptional level for key amplified genes. The genes 
falling in amplified/gained regions show an increased expression compared to those in 
lost/deleted regions, confirming the observations from the WGS data (Fig. 2c). This, 
together with results from IHC staining of matched cases, suggests phenotypic relevance 
of the genome-level findings (Fig. 2d). 
Overall, 40% of the samples have both receptor gain and downstream activation of at 
least one gene, 43% RTK gain alone, and a small number (2%) have downstream 
activation alone (Fig. 2e). We only see a single RTK gain, without gains or amplifications 
in the MAPK or PI3K pathways, in 9% of tumors, and in these cases, the RTKs involved 
are EGFR (4), ERBB2 (3), ERBB3 (1), FGFR1 (1), FGFR3 (1) and MET (1). The observed 
co-amplification patterns are unlikely to be biased by locus positioning, as the inspected 
RTKs have a varied distribution on chromosomes, so the co-amplifications in these 
genes appear to be selected for.  
We therefore surmised that tailored RTKi combination therapy might be beneficial in 
some cases and decided to explore this in in vitro model systems. Since copy number 
gain events were seen most commonly in ERBB2, EGFR, MET and FGFRs, a panel of small 
molecular inhibitors was selected to target these RTKs. As expected, a single agent did 
trigger a cytotoxic effect in cell lines with a gain at that locus, but only in the micromolar 
range (Fig. 2g). In cell lines with an ERBB2 and a MET amplification, a significant 
reduction in cell proliferation was observed when both RTKs were inhibited with a GI50 
down in the nanomolar range, for example OE33 (Fig. 2f, 2g, Table 1). A similar finding 
was observed in Flo (EGFR/MET copy gain) and OAC-P4C (ERBB2/FGFR2 amplification) 
when treated with EGFRi/METi and ERBB2i/FRFGi combinations, respectively. Taken 
together, these results suggest that a combination of RTK inhibitors tailored to the 
amplification profile might offer a clinical therapeutic strategy. Nevertheless, the 
complexity and diffuse patterns of these alterations provide a distinct challenge in the 
stratification of patients for therapy. 
 
Mutational signatures uncover distinct etiology in EAC 
 
In view of the heterogeneity and RTK-resistance mechanisms, we sought alternative 
therapeutic insights into the data using mutational signature analysis in a three-base 
context via the non-negative matrix factorization (NMF) methodology described by 
Alexandrov et al [29]. We also used the recently described pmsignature [30] and 
SomaticSignatures [31] for comparison. These methods are based on different statistical 
frameworks and therefore some differences are to be expected; nevertheless the same 
key signature patterns were observed with similar-sized patient subgroups expressing 
the dominant signature types (Supplementary Notes, Supplementary Fig. 9-12). Six 
signatures were prominent (Supplementary Fig. 13-14): S17, the hallmark signature of 
EAC [16, 17] dominated by T>G substitutions in a CTT context and possibly associated 
with gastric acid reflux – here renamed S17A; a previously uncharacterized variant of 
this signature combining a relatively higher frequency of T>C substitutions with the 
classical T>G pattern found in S17, which we call S17B; S3, a complex pattern caused by 
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defects in the BRCA1/2-led homologous recombination pathway; S2, C>T mutations in a 
TCA/TCT context, an APOBEC-driven hypermutated phenotype; S1, C>T in a *CG context, 
associated with aging processes; and an S18-like signature, C>A/T dominant in a 
GCA/TCT context, formerly described in neuroblastoma, breast and stomach cancers 
(Fig. 3a). The exploration of a seven-base signature context using pmsignature yielded 
an A/T base dominance at the -3 and -2 positions for the S17 signature, but no other 
striking  preferences for particular nucleotide combinations at the 2nd and 3rd bases for 
any of the other signatures  (Supplementary Fig. 15). Overall, this suggests that the 
bases immediately adjacent to the position where the mutation occurs exert the main 
bias, with a potentially more complex mechanism for the S17 signature.  
When considering the dominant mutation signatures on a per-patient basis, three 
subgroups of patients became apparent: C>A/T dominant (age, S18-like), DNA Damage 
Repair (DDR) impaired (BRCA), and mutagenic (predominantly S17A or S17B) (Fig. 3a). 
We chose the descriptor mutagenic because the mutation rate was significantly higher in 
this subgroup (Welch’s t-test p=0.0007; Supplementary Fig. 16). The robustness of the 
subgroups was ensured through consensus clustering and confirmed by silhouette 
statistics (Methods, Supplementary Fig. 17-18). We have also validated our findings in 
an independent cohort of 87 samples [18] and show that: when we apply the NMF 
method the same dominant signatures (S1, S2, S3, S17, S18-like) are observed; and 
when we perform clustering three subgroups emerge and these are of similar 
composition and proportions to those seen in the original cohort (Methods, Fig. 3b 
compared with Fig. 3a). Furthermore, the total mutational burden is again consistently 
higher in the mutagenic subgroup of the validation cohort. No cellularity bias or batch 
effect was observed among subgroups (Supplementary Fig. 19).  
To test whether spatial sampling might have induced a bias in the predicted 
signatures, we inspected three additional patients who had multiple samples taken. The 
mutational patterns showed remarkable consistency across all three biopsies, especially 
with respect to the dominant signature (Fig. 3c). This suggests that, despite the 
heterogeneity of this disease, the mutational signature analysis should be sufficiently 
robust to cope with spatial sampling bias.  
We next examined whether the defined subgroups presented similarities in terms of 
genomic characteristics. All three subgroups showed a similar degree of heterogeneity 
in copy number alterations by chromosomal arm (Supplementary Fig. 20), and the RTK 
co-amplification profiles were fairly similar among subgroups (Supplementary Fig. 21). 
Of note, the C>A/T dominant subgroup had a two-fold higher frequency of ERBB2/MET 
co-amplifications, but this did not reach statistical significance. 
The rearrangement patterns in the three subgroups denoted differences in genomic 
stability. In particular, unstable genomes were less frequent in the C>A/T dominant 
subgroup and most frequent in the DDR impaired subgroup, as defined by the structural 
variant (SV) based classification [11, 18] (Supplementary Fig. 22). When examining SV 
signatures in a similar manner using the NMF framework (Methods), the C>A/T 
dominant subgroup also had lower levels of large-scale duplications and an increased 
frequency of focal interchromosomal translocations, which suggest mobile element 
insertion events (Supplementary Fig. 23). The DDR impaired subgroup seemed to have 
the largest degree of genomic instability, even though SV signatures were overall rather 
heterogeneous. No recurrently altered genes (in >10% of the cohort) were over-
represented in any of the three subgroups after multiple testing correction, nor were 
there any differences in TP53 or HER2 status among the subgroups to account for the 
differences in genomic stability.  
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The clinical characteristics of the three subgroups did not differ significantly 
(Supplementary Table 5, Supplementary Fig. 24), implying that the classification, and 
hence spectrum of mutation patterns, does not vary with smoking, age, sex, tumor 
histopathological grade, tumor stage,  response to chemotherapy, overall or recurrence-
free survival etc. Hence, the mutation signature profiles seem to be capturing a different 
type of information compared with current clinical classification methods. 
 
Evidence of DNA damage repair deficiency in EAC 
 
 Next we investigated what aspects of the DNA damage response were defective in the 
DDR impaired subgroup. Although a BRCA signature was recovered, there were only 3 
nonsynonymous mutations and 3 germline variants (non-intronic) in either BRCA1 or 2 
in a total of 5 out of 18 patients, suggesting that other mechanisms were largely 
responsible for this signature (Supplementary Tables 6 and 7). We thus assessed the 
mutational rates across more than 450 genes associated with DDR, as previously 
described in a pan-cancer analysis [32] (Fig. 4, Methods). We found that there was a 4.3-
fold enrichment of samples with alterations in homologous recombination (HR) 
pathways in the DDR impaired subgroup compared to the others (95% CI [1.47, 12.56]). 
It is therefore likely that a pathway-level disruption of HR contributes to the BRCA-like 
mutational signature rather than mutations of BRCA genes.  
The analysis of DDR genes in the whole cohort unsurprisingly showed that the most 
mutated pathway was TP53 (Supplementary Fig. 25), and this was consistent among 
subgroups (Fig. 4a), as were the amplification and deletion patterns (Supplementary Fig. 
26). In addition, more than 24% of the genomes had defects in chromatin remodelling, 
comprising recurrently mutated genes like ARID1A (8%) and SMARCA4 (8%) (Fig. 4b). 
ARID1A is also recruited to DNA double strand breaks (DSB), where it facilitates 
processing to single strand ends [33]. Defects in ARID1A impair this process and 
sensitise cells in vitro and in vivo to PARP inhibition (PARPi) [33].  
 
 
Neoantigen burden coupled with etiological differences suggest new therapeutic 
avenues 
 
Modulation of the cytotoxic T cell response using monoclonal antibodies against the 
Programmed Death Receptor or Ligand (PD-1 and PD-L1 inhibitors), as well as those 
targeting CTLA4 (Ipilimumab) have shown promise in the treatment of solid tumors 
[34-36]. The recent literature suggests that both numbers of mutations and total 
neoantigen burden have been coupled with significantly better clinical responses to 
immunotherapy [37-39]. 
We found that the mutagenic subgroup, whose observed signature may be due to 
gastric acid reflux, harboured a significantly higher nonsynonymous mutational burden, 
as well as higher levels of neoantigen presentation (Welch’s t-test p=0.0007 and 
Wilcoxon rank-sum test p<<0.0001, respectively; Fig 5a and Supplementary Fig. 16). 
This is in keeping with that observed for lung cancer and metastatic melanoma, with a 
1.5-fold higher median neoantigen burden in this subgroup versus the rest – similar to 
the two-fold ratio reported by Rizvi et al [37, 40]. Using available microarray expression 
and RNA-Seq data, we observed a significantly higher number of neoantigens expressed 
in the mutagenic subgroup compared to the rest (Wilcoxon rank-sum test p-value = 
0.042, Fig. 5a). 
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In recent studies, an enriched population of pre-existing CD8+ T cells was shown to 
predict a favorable outcome from PD-1 blockade therapy [41, 42]. We found a higher 
density of CD8+ T cells in a subset of available samples from the mutagenic signature 
subgroup compared with samples from the other subgroups (Fig. 5a, 5b). 
 
Treatment responses in mutational signature subgroups 
 
Given the complexity of the RTK landscape and the apparent need to profile each patient 
to determine the optimal combination of RTK inhibitors, we hypothesised that the more 
homogeneous profile of mutational signatures - yet with discernable differences 
between the three subgroups in terms of mutation frequency and DDR pathways - might 
be a more clinically applicable starting point to guide therapy decisions. To start to test 
this hypothesis, we used newly derived cell line models from patients in the OCCAMS 
consortium with an available germline reference sequence from which we could derive 
the signatures:  OES127, DDR impaired profile; MFD, mutagenic profile; AH277, C>A/T 
dominant profile (Fig. 6a). For the DDR impaired profile we hypothesised that PARPi, 
with or without a DNA-damaging agent such as Topotecan, might be beneficial [33, 43, 
44]. Topoisomerase I (Topo1) is an enzyme required for DNA replication and when 
inhibited in combination with Olaparib it has been shown to generate synthetic lethality 
in BRCA deficient cases [45, 46]. No cytotoxic effect was observed when Olpaprib or 
Topotecan was used as single reagent, however, a marked synergistic effect was shown 
when Topotecan was combined with Olaparib for OES127 (DDR impaired group), but 
not for the other primary cell lines (Fig. 6b, Supplementary Table 8). 
Next we were interested to test the efficacy of Wee1/Chk1 inhibitors given the high 
frequency of p53 mutation in this disease [47, 48]. Several recent studies revealed that 
pharmacological inhibition of G2/M-phase checkpoint regulators Wee1 and Chk1/2 
resulted in an antitumorigenic effect in some highly mutated cancers [49, 50]. We 
therefore hypothesised that inhibition of mitotic checkpoints would be cytotoxic in EAC 
and that this might be more apparent in cells with a high mutation burden [51, 52]. As 
expected, a cytotoxic effect for these drugs was observed to some extent in all of our 
primary cell lines, but the sensitivity was increased in the AH277 and MFD lines in 
comparison with the p53 WT line OES127 (Fig. 6c, Supplementary Table 9). In the MFD 
cells with a mutagenic signature, there was a 25-fold and 10-fold increased sensitivity in 
response to the Wee1 and Chk1/2 inhibitor, respectively, compared with the AH277 
cells from the C>A/T dominant subgroup. 
These experimental data provide a starting point from which to evaluate therapeutic 
options derived from mutational signatures, especially as primary model systems more 
closely resembling human disease and with stromal components become available [53, 
54]. 
 
  
 
DISCUSSION 
 
Whole-genome sequencing of 129 EAC patients has unveiled a high prevalence of large-
scale alterations that may play an important role in the development of this cancer. 
Similarly to ovarian, breast and lung cancers which have been described as ‘copy 
number driven’ [55], relatively few genes were recurrently point-mutated (except  
TP53), but there were frequent recurrent amplifications in sites harbouring oncogenes, 
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deletions of important cell cycle components (CDKN2A, CDKN2B) and rearrangements 
of genes like RUNX1, frequently translocated in leukemias [56]. The highly 
heterogeneous landscape of potential genomic drivers explains the difficulties 
encountered to date in finding suitable avenues for tailored therapies. 88/262 
registered esophageal trials [28, 57] target RTKs and mitogenic signalling pathways 
with remarkably little clinical efficacy. The genomic and in vitro analyses of EAC cell 
lines performed here suggest that the high prevalence of co-amplification of RTKs and 
downstream mitogenic pathway genes is a likely cause for these disappointing results.  
Although all six mutational signatures are seen to a greater or lesser extent in most 
patient tumors, three distinct dominant subtypes, namely DDR impaired, C>A/T 
dominant, and mutagenic, point to specific etiological factors or genetic instabilities 
dominating the development of any individual’s EAC. We hypothesise that the insights 
obtained from mutational signatures could be harnessed for future studies that might 
investigate the potential of using tailored therapies to complement the current 
treatment options as summarized in Figure 7. 
In the DDR impaired subgroup with an enrichment for HR dysfunction, a synthetic 
lethality approach may prove useful. Indeed, HR scarring is a good a biomarker for the 
purposes of DDR targeted treatment [58], being well established in breast and ovarian 
cancer and more recently also reported in gastric tumors [59]. HR dysfunction renders 
tumors sensitive to platinum-based chemotherapy and PARPi, which has started to 
make a survival impact in other BRCA-related tumors [60]. Indeed, we also observe 
some increased sensitivity to platinum-based chemotherapy in the DDR impaired 
subgroup in our cohort (Supplementary Fig. 27). PARPi in combination with irradiation 
has shown to be potent in HR scarred tumors [61] and our data from a primary line with 
a DDR signature suggests that PARPi in combination with a DNA damaging agent might 
be beneficial.  
Expression of PD-L1 has been demonstrated in gastroesophageal tumors at all stages, 
and as such, PD-L1 based immunotherapy might be an an attractive therapeutic avenue 
needing further exploration in this disease [62]. Both the nonsynonymous mutation 
burden and the neoantigen level, as well as CD8+ cell infiltration, have been shown to be 
good genomic biomarkers in predicting response to immunotherapy in both smoking-
related non-small cell lung cancer and melanoma [37, 38, 42, 62]. In keeping with these 
other tumors which result from chronic exposure to mutagens (smoking and UV 
irradiation, respectively), we observe similar features in our mutagenic cohort 
containing an ‘acid’ signature. This type of genomic classification has also been proposed 
in other tumor types for patient stratification for immunotherapy [63] and warrants 
further investigation in this cancer. Similarly, Chk/Wee1 inbitors may be promising 
tools for future studies in highly mutated, p53-inactive tumours [49, 50]. 
Patients in the C>A/T dominant subgroup would continue to be treated with 
conventional chemotherapy until more progress is made, for example with synthetic 
lethality approaches combined with radiotherapy or mutant TP53 reactivating drugs 
[64-66]. Alternatively, combined RTK inhibitors (especially ERBB2 and MET, given their 
prevalence in this subgroup) may be beneficial and combined MEK and Akt inhibition 
might be worthy of consideration given the low levels of amplifications/activation seen 
downstream in the MAPK and PI3K pathways [67].   
One practical question that arises is how this approach could be implemented 
clinically. Despite the decreasing costs of WGS, it is still expensive and signatures are 
problematic to derive from whole-exome data [29].  However, lower coverage whole-
genome (10x), or even shallow (1x) genome sequencing could provide a cost-effective, 
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high-throughput alternative for signature-based stratification and we have  shown using 
simulations down to 10x that we can confidently retrieve dominant signatures at lower 
coverage (Supplementary Fig. 28). Moreover, while designing custom gene panels would 
pose serious difficulties in such a heterogeneous disease, mutational signature-based 
classification would enable us to bypass the tumor heterogeneity bottleneck by 
providing a genome-wide, spatially-independent classification strategy (Fig. 3c). 
For subsequent classification of individual patients, we propose using a quadratic 
programming approach whereby we predict exposures to the six mutational signatures 
without having to estimate a large set of parameters (as with the classical NMF 
algorithm) and use the dominant signature pattern for patient assignment (Methods). 
The example in Figure 7, performed for newly derived ICGC data, illustrates this fast and 
effective way of classifying new patients. This methodology is of course not without 
limitation: the age, S18-like and APOBEC signatures are currently grouped together, but 
in a much larger cohort a distinct ‘age’ or ‘APOBEC’ subgroup might emerge, with their 
own characteristics. Similarly, signatures S17A and S17B may merge into a single 
signature in a much larger cohort, as was the case for signatures S1A and S1B [29].  It 
should be borne in mind that algorithms for defining signatures are evolving with 
improved speed of computation [30] and there is inherent variation in sample 
categorization between methods. Methodology is also being developed to accurately 
identify signatures de-novo in single patients, which we expect will offer a promising 
alternative for patient stratification.  
In summary, we have uncovered possible reasons for the lack of efficacy in 
molecularly targeted trials thus far, and present a novel genomic classification of these 
tumors which links etiology to patient stratification with potential therapeutic relevance. 
Further studies will be needed for pre-clinical validation prior to implementation in 
trials, as well as to understand the extent to which this genomic distinction is 
maintained downstream, at the level of the transcriptome, proteome and cellular 
phenotype. 
 
METHODS 
 
Ethical approval, sample collection and DNA extraction 
 
The study was registered (UKCRNID 8880), approved by the Institutional Ethics 
Committees (REC 07/H0305/52 and 10/H0305/1), and all subjects gave individual 
informed consent. Samples were obtained from surgical resection or by biopsy at 
endoscopic ultrasound. Blood or normal squamous esophageal samples at least 5 cm 
from the tumor were used as a germline reference. All tissue samples were snap frozen 
at collection and stored at −80 °C. Before DNA extraction, one section of the sample was 
stained with hematoxylin and eosin and sent for cellularity review by two expert 
pathologists. Cancer samples with a cellularity ≥70% were submitted for whole-genome 
sequencing. DNA was extracted from frozen esophageal tissue using the AllPrep kit 
(Qiagen) and from blood samples using the QIAamp DNA Blood Maxi kit (Qiagen).  
A total of 129 cases (matched tumor-normal) were sequenced and analyzed in the 
study.  True esophageal and gastroesophageal (GOJ) type 1 and 2 tumors (according to 
Siewert classification) were used. All GOJ type 3 tumors (14 in total) were excluded from 
the analysis. This sample size constitutes a considerable increase from earlier WGS 
studies in this cancer [16, 17]  and is of similar size to whole-exome studies reported to 
date [16, 17], with the advantage of covering the full genome. It is expected, therefore, 
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that it should present enough power to detect a similar number of significant somatic 
events affecting genes, and an increased power to depict the landscape of larger scale 
alterations in EAC. 
 
Whole-genome sequencing analysis 
 
Whole-genome sequencing was performed on a tumor and matched normal sample for 
each patient in the cohort. A single library was created for each sample, and 100-bp 
paired-end sequencing was performed under contracts by Illumina and the Broad 
Institute to a typical depth of at least 50x for tumors and 30x for matched normals, with 
94% of the known genome being sequenced to at least 8x coverage and achieving a 
Phred quality of at least 30 for at least 80% of mapping bases. Read sequences were 
mapped to the human reference genome (GRCh37) using Burrows-Wheeler Alignment 
(BWA) 0.5.9 [68], and duplicates were marked and discarded using Picard 1.105 
(http://broadinstitute.github.io/picard). As part of an extensive quality assurance 
process, quality control metrics and alignment statistics were computed on a per-lane 
basis. 
The FastQC package was used to assess the quality score distribution of the 
sequencing reads and perform trimming if necessary. 
Samples were examined for potential microsatellite instability (MSI) using 
computational tools, and five cases with potential MSI were subsequently excluded from 
the analysis, as previously performed in other studies [16] (Supplementary Notes and 
Supplementary Table 10). 
 
Somatic mutation and indel calling 
 
Somatic mutations and indels were called using Strelka 1.0.13 [69]. SNVs were filtered 
as described in Supplementary Table 11. Functional annotation of the resulting variants 
was performed using Variant Effect Predictor (VEP release 75) [70]. 
Significantly mutated genes were identified using MutSigCV [24]. 
 
Copy number and loss of heterozygosity analysis 
 
For patient-derived samples, absolute genome copy number after correction for 
estimated normal-cell contamination was called with ASCAT-NGS v2.1 [71], using read 
counts at germline heterozygous positions estimated by GATK 3.2-2 [72]. 
Cellularity, expressed as the relative proportion of tumor and normal nuclei, was also 
obtained using ASCAT. It was distributed as follows: 18% of samples had cellularity 
<0.3; 71% of samples between 0.3 and 0.7; 11% of samples ≥0.7. 
Significantly amplified/deleted regions in the cohort were identified using GISTIC2.0 
[23], after correcting the copy numbers for ploidy (total copy number of the segment 
divided by the average estimated ploidy of each sample). GISTIC2.0 was run on an input 
defined as the log2 of such corrected copy number values, with gain (-ta) and loss (-td) 
thresholds of 0.1 and sample centering prior to analysis. Copy number change 
thresholds considered for downstream analysis were: amplifications, GISTIC score  ≥2; 
deletions, ≤-2. Loss of heterozygosity (LOH) was defined as ASCAT-estimated minor 
allele copy number of 0. 
A whole-genome duplication event was considered to have occurred in a sample if the 
average estimated ploidy by ASCAT was ≥3, similar to the cut-offs suggested in [73]. 
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For cell lines, copy number calling was performed using Control-FREEC [74]. 
 
RTK copy number profiling 
To examine the landscape of copy number alterations in RTKs and downstream key 
genes (Fig. 2), a score from -2 to 2 was used to denote: deletions (-2), losses (-1), gains 
(+1), amplifications (+2). For the patient derived samples, copy numbers estimated 
using ASCAT were subsequently classified according to GISTIC2.0 using the same 
scoring scheme. For the cell models, a GISTIC-equivalent score was derived by dividing 
the estimated copy numbers by Control-FREEC by the average ploidy of each cell line, 
and classifying regions ≥2 as amplified (equivalent score=2), regions ≤-2 as deleted 
(equivalent score=-2), and regions >1 or <1 as gained or lost, respectively (equivalent 
scores +1/-1). For the MFD line only the parent tumour was sequenced, so the copy 
numbers were inferred using ASCAT and GISTIC2.0 as described above. 
In Figure 2b, the average copy number value of downstream key genes is highlighted 
for each representative gene (e.g. RAS summarizes the copy number landscape of HRAS, 
KRAS, NRAS), hence the scores take continuous rather than discrete values as in panel 
2a. 
 
Structural variant and mobile element insertion calling and annotation 
 
Structural variants were called using BWA-mem for alignment [75], against the GRCh37 
reference human genome, followed by clustering of putative breakpoint junctions 
identified by discordant read pairs and split reads using Manta [76]. We then discarded: 
SVs overlapping gaps, satellite sequences, simple repeats >1000 basepairs or extreme 
read depth regions; and deletions of < 1000bp that were not supported by at least one 
split read defining the deletion junction. Small inversions up to 10 kb  were also 
discarded as they are generated artefactually in some libraries [77]. Breakpoints in 
genes were annotated against Ensembl GRCh37, version 75 [18]. Fragile sites were 
annotated from Le Tallec et al [78].  
SV calls that represented mobile element insertions—either because the mobile 
element transduced unique sequence or its polyA tail was mapped by the aligner  [21]—
were identified from lists in Paterson et al [21] and Tubio et al [22]. SVs likely to be 
additional mobile element transductions—extensions of known transduced sequence or 
sequences transduced by L1s that were not previously known to transduce—were also 
identified in the following way: (1) SVs were pooled from all tumors, and clusters of at 
least five interchromosomal breakpoint junctions within maximum 1 kb of each other 
identified; (2) from these, clusters harbouring five-fold more interchromosomal 
translocations than other types of SVs and where there were at least four different 
partner chromosomes to which the presumed transduced sequences were joined, were 
identified as likely additional mobile element transductions. Many were associated with 
known L1 polymorphisms [79]; as expected, around half had an SV at each end of the 
insert. This and increased sensitivity from using the BWA-MEM aligner considerably 
increased the number of SVs identified as inserts compared to [21]. 
When examining genes altered by SVs, a moderate correlation was found between the 
number of SVs affecting a gene and gene length (Pearson correlation coefficient = 0.4, 
Supplementary Fig. 29). To prioritize rearranged genes of potential impact in the cohort, 
we first performed the following filtering steps: (1) all annotated fragile sites were 
removed from the list of genes overlapping SVs; (2) to capture potential unannotated 
fragile sites, we scored all genes using the following scoring: 
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Sgene = Db×Np×Lgene , where Db = total breakpoint density along the genome over all 
samples where breakpoints cause internal deletions in the gene (number of such 
breakpoints divided by the length of the genome), Np = total number of patients where 
the gene presents internal deletions, and Lgene= length of the gene. 
Genes with scores >10-fold higher than the 99% quantile over the full list were 
filtered out as likely fragile sites (Supplementary Table 12). 
For the remaining set of genes, we scanned 100 kb windows along the genome, with 
50 kb overlap, for hotspots of SV breakpoints (defined as breakpoint accumulations 
within the window) and prioritized the top 1% hotspots with highest breakpoint density. 
Genes harbouring at least one such hotspot and rearranged in more than 10% of the 
patients were selected as top hits of potential impact in this cancer. 
 
Structural variant-based classification of genomes 
 
The structural variant-based classification was used to annotate unstable, stable, 
locally rearranged and scattered genomes as previously described [11], but with 
different cut-offs for stable and unstable genomes, to account for the different genomic 
instability landscape in EAC compared to pancreatic cancer: genomes were deemed 
“stable” if the total number of SVs was less than the 5% quantile in the cohort, and 
unstable if the number of SVs exceeded the 95% quantile. The criteria for locally  
rearranged and scattered genomes were kept the same as previously described. 
 
Mutational signature analysis 
 
Discovery 
Mutational signatures were identified using the NMF methodology described by 
Alexandrov et al [29]. Before running the software, common variants in the 1000 
genomes database [80] appearing in at least 0.5% of the population were removed, and 
samples with cellularity <25% (from ASCAT estimates) were not included, leaving a 
total of 120 samples for the analysis. The optimal number of signatures in the dataset 
was chosen to balance the signature stability against the Frobenius reconstruction error 
(Supplementary Fig. 13). To increase confidence in the findings, two other methods 
were also used: the R packages pmsignature [30] and SomaticSignatures [31] 
(Supplementary Notes and Supplementary Fig. 9-12).  
To establish which of the two C[T>G]T signatures resembled most the classical S17 
signature recorded in the COSMIC database, we used the cosine similarity distance 
measure between the probability vectors of these signatures. The signature which we 
termed S17A had a higher cosine similarity distance compared to S17B (0.98 versus 
0.92), and we hence considered it to be more reflective of the signature reported in the 
literature. 
Samples in the discovery cohort were clustered by their signature exposures using a 
consensus clustering approach [81] (based on Pearson correlation distance with 
complete linkage) in order to increase the robustness of the subgroup assignment.  
 
Validation 
The three mutational signature subgroups were validated in an independent cohort 
of 87 EAC samples (21 from [18] and 66 independent patients in our  ICGC study post-
neoadjuvant therapy and surgery). These had been selected from a slightly larger cohort 
after removing low cellularity and MSI positive samples. Within the validation cohort, 
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the same dominant signatures were inferred using the NMF method, as above. The 
signature contributions were estimated based on the six main processes inferred in the 
test cohort using quadratic programming (described later in the Methods). 
 
Multiple sampling 
To test the differences in mutational exposures coming from three different spatial 
locations within the same sample, we have used three available cases for which multiple 
samples had been collected from the same tumour. We obtained the mutational 
exposures for the six described signatures using quadratic programming. 
 
Structural variant signature analysis 
 
Similar to inferring mutational signatures, we used the methodology by Alexandrov et al 
[29] to discover structural variant signatures in EAC genomes. We classified structural 
variants (deletions, inversions, insertions, interchromosomal translocations) by their 
size and distribution along the genome. SVs were grouped by size into “small” and 
“large”, defined with respect to the 25% quantile length in the cohort for the respective 
SV type). To determine the SV distribution along the genome, we assessed the degree of 
clustering within 10 Mb windows along the genome. If the SV of interest fell within a 
window of clustered events (where the total number of SVs exceeded 1.5x the 75% 
quantile of the total number of events in that genome), then it was deemed a “focal” 
event. Otherwise, it was catalogued as “genomically distributed”. These characteristics 
defined a total of 14 features to be used for signature discovery (Supplementary Fig. 23). 
 
Identification of catastrophic events 
 
Kataegis was called in a similar manner to Nones et al [18], by calculating the distance 
between consecutive mutations and segmenting the resulting genome-wide signal using 
piecewise constant fitting as implemented in the copynumber Bioconductor package [82] 
(Supplementary Fig. 5). However, acknowledging that the intermutational distance 
distribution varies from genome to genome, we did not use a fixed cutoff of 1000 bases 
for the mean distance between mutations in kataegis loci, but instead applied a variable 
cutoff that was determined as the 1% quantile of the intermutational distances within 
the respective genome. 
Chromothripsis events were identified in chromosomes containing >10 CN steps, 
according to the criteria described by Korbel and Campbell [83] and Nones et al [18]: (a) 
clustering of breakpoints; (b) regularity of oscillating CN steps; (c) interspersed loss and 
retention of heterozygosity; (d) randomness of DNA segment order and fragment joins; 
(e) ability to walk the derivative chromosome. Scripts were developed to assess these 
criteria, and the final chromothripsis calls were prioritized through visual inspection 
(Supplementary Fig. 6).  
Regions of clustered inversions were identified as a proxy for BFB and complex 
rearrangement events. These were defined by scanning for enrichments of inversions 
(1.5x the upper quantile of the total number of events in the genome) within 5-Mb 
windows throughout the genome. Visual inspection was used to prioritize those regions 
that displayed BFB-like characteristics. Several types of complex rearrangement events 
were identified: focal amplifications with BFB pattern (clustered inversions along with 
progressive amplification steps primarily on one side of the inversion cluster, i.e. 
asymmetric); other focal amplifications within narrow regions <5 Mb (clustered 
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inversions coupled with copy number amplifications displaying an irregular pattern), 
focal amplifications within wider 5-10 Mb regions (clustered inversions and progressive 
copy number amplification steps, often with multiple peaks); double minute-like 
patterns (clustered inversions at high copy number amplification regions without 
evidence of a progressive mechanism); potential subtelomeric BFBs (amplifications 
located close to the ends of the chromosomes, coupled with inversion clusters and distal 
deletions). See Supplementary Figure 7 for sample illustrations of the patterns 
described.  
 
 
DNA damage repair (DDR) analysis 
 
To assess the alterations in DNA damage-related pathways, we performed an analysis 
similar to the one described by Pearl et al [32]. Among the genes involved in defined 
DNA damage pathways as described in the paper, we only selected those affected more 
often than the expected background of synonymous mutations, similar to the method 
described by Puente et al [84]. The probability of a gene being affected by M 
nonsynonymous mutations in the cohort follows a poisson binomial distribution and is 
calculated relative to a basal probability depending on the number of nonsynonymous 
(𝑛𝑛𝑠) and synonymous (𝑛𝑠) mutations, gene size (L), local mutational density for the 
locus (d) and total length of coding regions in the genome (E) as follows: 
𝑃𝑛𝑠 =
𝑛𝑛𝑠𝐿𝑑
(𝑛𝑛𝑠 + 𝑛𝑠)𝐸
 
Subsequently, we catalogued those that harboured nonsynonymous somatic 
mutations/indels with possible deleterious effect (as predicted by SIFT [85]/PolyPhen 
[86]) or copy number alterations (amplifications and deletions using the defined GISTIC 
cut-offs) in our cohort. We then compared the mutational load in 16 main pathways 
among the defined mutational signature subgroups. 
 
Neoantigen predictions and analysis 
 
In order to quantify the neoantigen load in the tumors, we performed the analysis as 
described in [37]. We first collected all peptides defined by a 17 amino-acid region 
centered on the amino acid which changes upon the mutation. We identified mutant 
nonamers with ≤500 nM binding affinity for patient-specific class I human lymphocyte 
antigen (HLA) alleles, constituting potential candidate neoantigens. Binding affinities 
were predicted using NetMHC-3.4 [87]. We then quantified the peptides that displayed 
high affinity binding in tumor, but low or no binding in the respective matched normal 
and obtained total counts for each defined mutational subgroup.  The neoantigen burden 
in tumours belonging to the different subgroups varied as follows: DDR impaired – an 
average of 77 (s.d. = 42.2); C>A/T dominant – an average of 86 (s.d. = 41.3); mutagenic – 
an average of 111 (s.d. = 43.9).  The three groups presented unequal variance in terms of 
nonsynonymous mutation burden, as shown by pairwise F-tests (p<0.05 after multiple 
testing correction using the Benjamini-Hochberg method). To adjust for this, the 
mutation burden among subgroups was compared using Welch’s t-test. The neoantigen 
load, on the other hand, had similar variance between the mutagenic group and the 
other two groups combined (F-test p>0.05), so the Wilcoxon rank-sum test was used to 
compare the predicted neoantigen presence in tumors. 
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To verify that the predicted neoantigens were indeed expressed in the samples, 
microarray and RNA-Seq derived expression Z-scores were investigated and all peptides 
with a score higher than the average in the respective sample were considered 
expressed. 
 
Microarray expression profiling 
 
Purified Total RNA was extracted using the AllPrep DNA/RNA Mini Kit from Qiagen. 
Quality of RNA was assessed using the NanoDrop and the Agilent Bioanalyser, and only 
samples with RIN>7 were accepted for microarray or RNA-Seq. The Illumina HTv4.0 
beadchip was used as platform for expression analysis. Bead level readings were 
corrected for spatial artefacts and the signal per probe ratio was computed. Relative 
array weights were applied before quantile normalization for gene expression analysis. 
For the validation of RTK gains/losses and neoantigen expression, available 
microarray data for a total of 42 samples were used. To evaluate expression levels for 
selected genes, Z-scores were obtained relative to the average expression in the sample 
or of the specific investigated gene.  
 
RNA sequencing and analysis 
 
Purified total RNA was subject to ribosomal depletion using methods already published 
[88]. In brief, 195 DNA oligonucleotides (Sigma Life Sciences) were pooled together in 
equal molar amounts  and incubated with total RNA Hybridase Thermostable RNase H 
(Epicentre). RNaseH-treated RNA was purified using 2.2x RNAClean SPRI beads 
(Beckman Coulter LifeSciences) and oligonucleotides removed using TURBO DNase 
rigorous treatment. A further purification of the DNase-treated RNA with 2.2x RNAClean 
SPRI beads was followed by library preparation using the TruSeq HT Stranded mRNA kit 
according to the manufacturers instructions (Illumina) and generated single end reads 
using the HiSeq 2500. 
For the validation of neoantigen expression, available RNA-Seq data for a total of 18 
samples were used. To evaluate expression levels for selected genes, Z-scores were 
obtained relative to the average expression in the sample.  
 
Cell lines and reagents 
 
The primary cell line panel was derived from EAC cases included in the ICGC sequencing 
study , including MFD (Tim Underwood, Southampton, OCCAMS consortium member), 
OES127 (Anna Grabowska, Nottingham, OCCAMS consortium member) and AH277 
(organoid, Mathew Garnett, Cambridge). The MFD line required 10% fetal calf serum 
(PAA) in DMEM medium (Invitrogen, ThermoFisher Scientific) and the AH277 culture 
method was as previously described [53]. The feeder layer system was used to expand 
OES127 lines. The established EAC lines, SK-GT-4, OAC-P4C, OACM5.1C, and OE33 were 
cultured in RPMI medium (Sigma) with 10% fetal calf serum, except for Flo, which was 
grown in DMEM with 10% fetal calf serum. The identity of all cell lines was verified by 
short tandem repeat (STR) profiling. All cells were routinely examined for mycoplasma 
contamination. 
Small molecular inhibitors used for treatment were: Lapatinib, AZD-4547, Olaparib, 
MK-1775 and AZD-7762 (BioVision), Crizotinib (LKT Labs) and Topotecan (Cayman 
Chemical). Inhibitors were diluted to working concentrations in DMSO (Sigma). 
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Immunohistochemistry 
 
Sections of 3.5 μm were stained by a Bond Max autostainer according to the 
manufacturer’s instruction (Leica Microsystems). Primary antibodies ERBB2 (1:300, Cell 
Signaling Technology), MET (1:300, Cell Signaling Technology), CD8 (1:100, Dako) were 
optimised and applied with negative controls. 
CD8+ cells were counted manually in two tumour areas of 1 mm2 each (except in one 
case where there was sufficient material for one count only) and an average was 
calculated. 
 
Drug sensitivity assays 
 
The seeding density for each line was optimised to ensure cell growth in the logarithmic 
growth phase. Cells were seeded in complete medium for 24 hours then treated with 
compounds at 4-fold serial dilutions for 72 hours. Cell proliferation was assessed using 
CellTiter-Glo (Promega). The anchor inhibitors were kept constant at 1M in combination 
studies. 
The concentrations of a compound causing 50% growth inhibition relative to the 
vehicle control (GI50) were determined by nonlinear regression dose-response analysis 
and the area under the curve (AUC) was calculated using GraphPad Prism. 
 
Proposed approaches to classifying new patients 
 
Classification of new patients based on their mutational signatures could be performed 
in either of the following ways: 
1. By examining the mutational exposures to signatures after running the sample 
together with a defined panel of tumors (currently, the 120 sample cohort) 
through the NMF pipeline. 
2. By fitting the mutational counts in the respective genome to a model defined 
based on the mutational probabilities (as recorded in the COSMIC database) for 
the six oesophageal signatures using quadratic programming. Quadratic 
programming is well suited for this type of problem, as it tries to optimize the 
signature exposures under the constraint that they should add up to one. 
The advantage of the latter approach is that it reduces the problem to a linear one, 
and thus the computation time is dramatically reduced. Moreover, no pre-defined panel 
of samples is needed for the method, only the expected distribution of nucleotide 
substitutions for the mutational signatures of interest (obtained from COSMIC or from 
the initial outcomes using the NMF pipeline). 
We model the observed mutation count vector Y (96 possible contexts) on the six 
mutational signature processes 𝑆𝑆 discovered as follows: 
𝑆 = 𝛑𝛑𝛑𝛑 +𝛑𝛑𝛑𝛑 +𝛑𝛑𝛑𝛑 +𝛑𝛑𝛑𝛑 +𝛑𝛑𝛑𝛑 +𝛑𝛑𝛑𝛑 +𝛑 
with ∑ 𝑆𝑆 = 1𝑆  and 𝑆𝑆 ≥ 0. We minimize 
 ∑(𝑆𝑆 − (∑𝑆𝑆𝑆𝑆𝑆))
𝑆𝑆
2
 
subject to these constraints, where i=1..N signatures and j=1..M contexts. 
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Statistics 
 
All statistical tests were performed using a Wilcoxon rank-sum test or ANOVA (for 
continuous data), and a Fisher exact test or Chi-square test (for count data). Welch’s t-
test was used when comparing groups of unequal variance. Multiple testing corrections 
were performed where necessary using the Benjamini-Hochberg method. All reported 
p-values were two-sided.  
 
Code availability 
 
The scripts used to perform the analysis are available upon request. 
 
Accession codes 
 
The whole-genome sequencing data can be found at the European Genome-phenome 
Archive (EGA) under accession EGAD00001001457. 
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Table 1. In vitro cytotoxicity of RTKi as single or combined reagents in EAC cell 
lines. Key RTK amplification status and drug targets are shown. Highlighting indicates 
that a synergic effect of the combination treatment was observed.    
 
Cell line RTK status RTKi GI50 (95% CI) (nM) AUC 
OE33 ERBB2/MET Amp 
Lapatinib (EGFR/ERBB2) 3.92 x103 (3.16-4.87 x103) 195.7 
Crizotinib (MET) 317.3 (166.3-605.4) 108.8 
Lapatinib + Crizotinib 6.56 (2.42-17.84) 47 
SK-GT-4 ERBB2 Amp/MET Gain 
Lapatinib (EGFR/ERBB2) 3.72 x103 (2.27-6.08 x103) 173.9 
Crizotinib (MET) 3.47 x103 (2.90-4.15 x103) 183.2 
Lapatinib + Crizotinib 530 (273.1-1029) 120 
OAC-P4C ERBB2/FGFR2 Amp 
Lapatinib (EGFR/ERBB2) 2.28 x103 (1.34-3.90 x103) 159.1 
AZD-4547(FGFR1/2/3) 3.82 x103 (3.32-4.40 x103) 194.7 
Lapatinib + AZD-4547 373.2 (260.9-533.7) 104.8 
Flo EGFR/MET Gain 
Lapatinib (EGFR/ERBB2) 
11.64 x103 (7.80-17.39 
x103) 
212 
Crizotinib (MET) 1.90 x103 (1.51-2.39 x103) 159.3 
Lapatinib + Crizotinib 243.4 (78.0-759.5) 109 
OES127 ERBB2 Amp/MET Gain 
Lapatinib (EGFR/ERBB2) 1.14 x103 (0.68-1.90 x103) 139.6 
Crizotinib (MET) 3.09 x103 (2.35-4.05 x103) 173.4 
Lapatinib + Crizotinib 587.7 (450.5-766.7) 117.5 
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Figure 1. Recurrent genomic events in the cohort (n=129). The top panel highlights the total number 
of protein-coding genes affected by copy number or structural changes (above the 0 axis), and point 
mutations or indels (below the 0 axis), respectively, for every patient (depicted on the X-axis). (a) The top 
rearranged genes, excluding fragile sites, containing structural variant hotspots and recurrent in >10% of 
patients. *INK4/ARF comprises the CDKN2A/2B locus. (b) Fragile sites rearranged in at least 20% of the 
patients. (c) Mobile element (ME) insertions detected by structural variant analysis, plotted on a log2 
scale. Grey tiles correspond to cases without any evidence of ME insertions. (d) Loci that are significantly 
amplified/deleted according to GISTIC2.0 and that are recurrent in >10% of the patients. The most 
extreme copy number alteration within the locus is shown for each patient (see Supplementary Tables 2 
and 3 for lists of genes in such loci). Only amplification and deletions are counted for the frequency 
histogram. (e) Genes altered by nonsynonymous SNVs/indels, deemed significantly mutated by MutSigCV. 
Loss of heterozygosity (LOH) regions are indicated in black rectangles when the gene also presents a 
mutation, indicating likely loss of function. (f) Presence of genomic catastrophes. (g) Cellularities, 
estimated by histopathology (H) or computationally using ASCAT (A). All samples sequenced have passed 
the histopathological cellularity cut-off of 70%. The total frequency of a specific gene alteration or event in 
the cohort is shown on the right-hand side for each panel. 
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Figure 2. RTK copy number profiling and responses to targeted RTK therapy (n=129). (a) RTK copy 
number gains/losses in the cohort of patient-derived samples and 9 cell models. The copy number scores 
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refer to: amplifications (2), homozygous deletions (-2), relative gains/losses (+1/-1) (Methods). Columns 
correspond to samples, ordered by the average ploidy. Samples with average ploidy ≥3 are highlighted as 
potentially whole-genome duplicated. (b) Copy number alterations in key genes of downstream pathways 
(c) Expression of RTKs and downstream key genes in patient-derived samples with gains (light red) 
versus losses (light blue) of the respective genes. An asterix (*) marks p-values<0.05 after multiple testing 
correction. (d) IHC staining of selected samples displaying consequences of copy number loss/gain in 
ERBB2 and MET. The GISTIC score (CN) is marked in every case. (e) Breakdown of major resistance 
mechanisms to RTK-based monotherapy within the patient-derived sample cohort and the cell line cohort. 
“Amplified” for this analysis denotes anything with a score ≥1. (f) Growth curve of OE33 cell lines after 72-
hour exposure to Lapatinib, Crizotinib and in combination. Mean values as a percentage of DMSO treated 
cells and ±SD for three experiments are shown. Olaparib used in combination was kept at 1μM.  (g) The 
effects of Lapatinib, Crizotinib and in combination on the cell lines with varying RTK status. Cell lines were 
grouped by the status of its relative RTK copy number into non-, ERBB2 amplification, and ERBB2 (or 
EGFR)/MET co-amplification. Error bars represent the standard deviation. An asterix(*) indicates p-
values <0.05. 
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Figure 3. Mutational signature-based clustering reveals differences in disease etiology in the 
cohort and is spatially consistent within a single tumor. (a) The heat map highlights the sample 
exposures to six main mutational signatures, as identified in the cohort (n=120) using the NMF 
methodology. The strength of exposure to a certain signature may vary from 0% to 100% (on a color scale 
from grey to red). Three main subgroups can be observed from the clustering based on the predominant 
signature: C>A/T dominant (S18-like/age) – 38 samples, DDR impaired (BRCA) – 18 samples, and 
mutagenic (S17) – 64 samples. The TP53, HER2 status, and catastrophic event distribution in the 
corresponding genomes are highlighted below (no significant difference observed among subgroups). The 
total mutational burden is significantly higher in the mutagenic subgroup. Consensus clustering was used 
for the heat map (Methods). b) Validation of the mutational signature-based clustering in an independent 
cohort (n=87). Unsupervised hierarchical clustering (Pearson correlation distance, Ward linkage method) 
reveals three main subgroups, similar to the ones in the discovery cohort: (1) S3 (BRCA) dominant – 
purple, 22% of the cohort; (2) mixed S18-like and S1 (age) – orange, 25% of the cohort; (3) S17A/B 
dominant – green, 53% of the cohort. The total SNV burden is also highlighted, confirming higher 
abundance in the mutagenic subgroup. c) Mutational signature contributions in three cases with multiple 
sampling from the same tumor. The relative exposures to the 6 signatures are highlighted on a grey-to-red 
gradient for each case. The group assignment is based on the dominant signature. 
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Figure 4. DNA  damage repair pathways altered through nonsynonymous mutations/indels in the 
cohort. (a) For each of the three defined subgroups, the percentage of patients harboring defects in the 
different DDR-related pathways is shown. Only nonsynoymous mutations in genes mutated in the cohort 
significantly more compared to the expected background rate and predicted to be potentially damaging to 
the protein structure (Methods) have been considered in the analysis. (b) HR, CR and CPF genes altered in 
the three subgroups (the numbers in the gradients indicate how many patients have mutations in the 
respective gene). AM, alternative mechanism for telomere maintenance; BER, base excision repair; CPF, 
checkpoint factor; CR, chromatin remodelling; CS, chromosome segregation; DR, direct repair; FA, Fanconi 
anaemia pathway; HR, homologous recombination; MMR, mismatch repair; NER, nucleotide excision 
repair; NHEJ, non-homologous end joining; OD, other double-strand break repair; TLS, translesion 
synthesis; TM, telomere maintenance; UR, ubiquitylation response. 
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Figure 5. Neoantigen burden is significantly higher in the mutagenic subgroup and associates with 
an increased CD8+ T-cell density. (a) From left to right: (1) Neoantigen burden compared among the 3 
mutational signature subgroups shows significant differences. A two-sided Welch’s t-test was used to 
compare the mutagenic group to the rest; (2) Microarray and RNA-Seq data available for a subset of the 
samples (25 from the mutagenic subgroup and 21 from the others) reveals that the number of expressed 
potential neoantigens is significantly higher in the mutagenic subgroup (Wilcoxon rank-sum test p = 
0.042); (3) Numbers of CD8+ T cells per mm2 observed in patients. Patients were grouped into the 
mutagenic group and BRCA+C>A/T dominant group. (d) Two representative images of CD8 IHC staining 
from each group. Magnification: x200. 
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Figure 6. Treatment response in different mutational signature groups. (a) Three cell lines, OES127, 
MFD and AH277 have been derived, each representative of a distinct signature-dominant subgroup: DDR 
impaired (OES127), mutagenic (MFD) and C>A/T dominant (AH277). (b) Growth curves of OES127 cell 
lines after 72-hour exposure to Olaparib, Topotecan and in combination. Mean values as a percentage of 
DMSO treated cells and ±SD for three experiments are shown. Olaparib used in combination was kept at 
1μM. (c) Growth curve of MFD cell lines after 72-hour exposure to MK-1775 and in AZD-7762. Mean 
values as a percentage of DMSO treated cells and ±SD for three experiments are shown.  
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Figure 7. Proposed subclassification of EAC based on mutational signatures informs etiology and, 
consequently, potential tailored therapies to be further investigated for the disease. Patients are 
currently treated uniformly, but classification based on mutational signatures may enable targeted 
treatments that would complement classical therapy routes and potentially achieve more durable 
responses. The highlighted box (right) exemplifies classifying new patients into the defined etiological 
categories based on mutational signatures using a quadratic programming approach (see Methods). The 
bars highlight the relative contributions of the six expected signatures to the observed mutations in 7 new 
tumors (not part of the 129 sample cohort). The dominant signature is indicative of the group to which 
the sample should be assigned. 
 
 
